Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase III Study of Paclitaxel, Ifosfamide and Cisplatin Versus Vinblastine, Ifosfamide and Cisplatin as Second-Line Therapy for Patients With Relapsed/Resistant Germ Cell Tumors

NCT00072215 is registered in ClinicalTrials.gov with Alliance for Clinical Trials in Oncology as lead sponsor.

NCT NCT00072215
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00072215 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase III Study of Paclitaxel, Ifosfamide and Cisplatin Versus Vinblastine, Ifosfamide and Cisplatin as Second-Line Therapy for Patients With Relapsed/Resistant Germ Cell Tumors
Lead sponsor
Alliance for Clinical Trials in Oncology
Phase
Phase 3
Overall status
Terminated
Start date
April 30, 2004
Completion date
April 30, 2005
Enrollment
1 (actual)
Sites
79

Conditions

As the registry lists them; a condition with its own page is linked.

extragonadal germ cell tumor, testicular germ cell tumor